Skip to main content

Recent Publications

Browse recent studies from the Lou and Jean Malnati Brain Tumor Institute to learn more about our cutting-edge research.

  1. Geller JI, Renfro LA, Grundy PE, Perlman EJ, Kalapurakal JA, Ehrlich PF, Biegel J, Huff V, Warwick AB, Paulino A  et al.  Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321.  Pediatr Blood Cancer  2025 Mar;72(3):e31490. doi:10.1002/pbc.31490
  2. Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA  et al.  Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580.  Int J Radiat Oncol Biol Phys  2025 Feb 01;121(2):571-572. doi:10.1016/j.ijrobp.2024.08.041
  3. Wu Y, Gao X, Liu Z, Wang P, Wu Z, Li Y, Zhang T, Liu T, Liu T, Li X  Decoding Cortical Folding Patterns in Marmosets Using Machine Learning and Large Language Model.  Neuroimage  2025 Jan 24;:121031. doi:10.1016/j.neuroimage.2025.121031
  4. Pedder JH, Sonabend AM, Cearns MD, Michael BD, Zakaria R, Heimberger AB, Jenkinson MD, Dickens D  Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease.  Lancet Neurol  2025 Jan 22;. pii:S1474-4422(24)00476-9
  5. Armstrong AE, Daw NC, Renfro LA, Geller JI, Kalapurakal JA, Khanna G, Paulino AC, Perlman EJ, Ehrlich PF, Gow KW  et al.  Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies.  Cancer  2025 Jan 15;131(2):e35713. doi:10.1002/cncr.35713
  6. Kotecha R, Akdemir EY, Kutuk T, Ilgin C, Ahluwalia MS, Bi WL, Blakeley J, Dixit KS, Dunn IF, Galanis E  et al.  Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design.  Neuro Oncol  2025 Jan 14;. pii:noaf009
  7. Du R, Zhang J, Lukas RV, Tripathi S, Ahrendsen JT, Curran MA, Dmello C, Zhang P, Stupp R, Rao G  et al.  Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?  Neuro Oncol  2025 Jan 12;27(1):33-49. doi:10.1093/neuonc/noae193
  8. Fernandopulle MS, Cotty-Fattal Z, Smith H, Mejia Bautista M, Ahrendsen JT, Jennings LJ, Santana-Santos L, Sukhanova M, Conway K, Primdahl D  et al.  Dual TERT promoter mutations in an oligodendroglioma, IDH-mutant, 1p/19q co-deleted.  J Neuropathol Exp Neurol  2025 Jan 11;. pii:nlae138
  9. Duckett D, Vormittag-Nocito ER, Jamshidi P, Sukhanova M, Parker S, Brat DJ, Jennings LJ, Santana-Santos L  Accurate identification of primary site in tumors of unknown origin (TUO) using DNA methylation.  NPJ Precis Oncol  2025 Jan 10;9(1):8. pii:8
  10. Khalili BF, Walbert T, Horbinski C, Dixit K, Gururangan K, Thio H, Tate MC, Stupp R, Lukas RV, Templer JW  Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.  Future Oncol  2025 Jan 09;:1-9. doi:10.1080/14796694.2025.2450215
  11. Malhotra J, Mambetsariev I, Gilmore G, Fricke J, Nam A, Gallego N, Chen BT, Chen M, Amini A, Lukas RV  et al.  Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.  JAMA Oncol  2025 Jan 01;11(1):60-69. doi:10.1001/jamaoncol.2024.5218
  12. Ziu M, Halasz LM, Kumthekar PU, McGranahan TM, Lo SS, Olson JJ  Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.  J Neurooncol  2025 Jan;171(2):279-298. doi:10.1007/s11060-024-04861-6
  13. Smith H, Jean J, Duckett D, Vormittag-Nocito E, Nezami BG, Jennings LJ, Ahrendsen JT, Yang XJ, Primdahl D, Conway K  et al.  Diagnostic utility of multimodal advanced molecular testing to classify metastases of unknown primaries: A case of a patient with no known medical history.  J Neuropathol Exp Neurol  2025 Jan 01;84(1):84-86. doi:10.1093/jnen/nlae086
  14. Gould A, Luan Y, Hou Y, Korobova FV, Chen L, Arrieta VA, Amidei C, Ward R, Gomez C, Castro B  et al.  Endothelial Response to Blood-Brain Barrier Disruption in the Human Brain.  JCI Insight  2024 Dec 26;. pii:e187328
  15. Dmello C, Brenner A, Piccioni D, Wen PY, Drappatz J, Mrugala M, Lewis LD, Schiff D, Fadul CE, Chamberlain M  et al.  Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.  Neurooncol Adv  2024;6(1):vdae186. pii:vdae186
  16. Baskaran AB, Kozel OA, Venkatesh O, Wainwright DA, Sonabend AM, Heimberger AB, Lukas RV  Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review.  Cancers (Basel)  2024 Dec 12;16(24). pii:4148
  17. Geng Y, DeLay SL, Chen X, Miska J  It Is Not Just About Storing Energy: The Multifaceted Role of Creatine Metabolism on Cancer Biology and Immunology.  Int J Mol Sci  2024 Dec 11;25(24). pii:13273
  18. Seblani M, Zannikou M, Duffy J, Levine R, Thakur A, Puigdelloses-Vallcorba M, Horbinski C, Miska J, Hambardzumyan D, Becher O  et al.  IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.  Res Sq  2024 Dec 11;. pii:rs.3.rs-5398280
  19. McCord M, Sears T, Wang W, Chaliparambil R, An S, Sarkaria J, James CD, Ruggeri B, Gueble S, Bindra R  et al.  The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.  Neuro Oncol  2024 Dec 10;. pii:noae257
  20. Moawad AW, Janas A, Baid U, Ramakrishnan D, Saluja R, Ashraf N, Maleki N, Jekel L, Yordanov N, Fehringer P  et al.  The Brain Tumor Segmentation - Metastases (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI.  ArXiv  2024 Dec 09;. pii:arXiv:2306.00838v3
  21. Leclair NK, Choudury A, Chen WC, Magill ST, McCortney K, Horbinski CM, Chen Z, Goldschmidt E, Eaton CD, Bulsara KR  et al.  RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.  Neuro Oncol  2024 Dec 05;26(12):2222-2236. doi:10.1093/neuonc/noae150
  22. Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD  et al.  Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.  JAMA Oncol  2024 Dec 01;10(12):1637-1644. doi:10.1001/jamaoncol.2024.4361
  23. Dean DC, Tisdall MD, Wisnowski JL, Feczko E, Gagoski B, Alexander AL, Edden RAE, Gao W, Hendrickson TJ, Howell BR  et al.  Quantifying brain development in the HEALthy Brain and Child Development (HBCD) Study: The magnetic resonance imaging and spectroscopy protocol.  Dev Cogn Neurosci  2024 Dec;70:101452. pii:101452
  24. Thirunavu V, Drumm M, McCord M, Steffens A, Youngblood MW, Nandoliya KR, Smith H, Walshon J, McCortney K, Magill ST  et al.  Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis.  J Neurosurg  2024 Dec 01;141(6):1644-1654. doi:10.3171/2024.4.JNS232857
  25. Kostelecky N, Wadhwani N, Golubovich I, Vormittag-Nocito E, Gao J, Jennings L, Caron M, Jamshidi P, Ahrendsen JT, Castellani R  et al.  Transdifferentiation of metastatic melanoma into cerebellar angiosarcoma.  J Neuropathol Exp Neurol  2024 Dec 01;83(12):1081-1083. doi:10.1093/jnen/nlae075
  26. Ross JL, Puigdelloses-Vallcorba M, Piñero G, Soni N, Thomason W, DeSisto J, Angione A, Tsankova NM, Castro MG, Schniederjan M  et al.  Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations.  Immunity  2024 Nov 12;57(11):2669-2687.e6. doi:10.1016/j.immuni.2024.09.007
  27. Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R, Arrieta VA, Dmello C, Chen L  et al.  Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.  Neuro Oncol  2024 Nov 04;26(11):2044-2060. doi:10.1093/neuonc/noae135
  28. Nandoliya KR, Congivaram H, Youngblood MW, Chen WC, Chaliparambil RK, Horbinski CM, Choudhury A, Brat DJ, Chandler JP, Magill ST  et al.  Clinical and methylomic features of spinal meningiomas.  J Neurooncol  2024 Nov;170(2):277-287. doi:10.1007/s11060-024-04736-w
  29. Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L  et al.  A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.  Clin Cancer Res  2024 Nov 01;30(21):4856-4865. doi:10.1158/1078-0432.CCR-24-1161
  30. Wang JZ, Patil V, Landry AP, Gui C, Ajisebutu A, Liu J, Saarela O, Pugh SL, Won M, Patel Z  et al.  Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.  Nat Med  2024 Nov;30(11):3173-3183. doi:10.1038/s41591-024-03167-4
  31. Cohen-Nowak AJ, Hill VB, Kumthekar P  Diagnostics and Screening in Breast Cancer with Brain and Leptomeningeal Metastasis: A Review of the Literature.  Cancers (Basel)  2024 Oct 31;16(21). pii:3686
  32. Tan S, Zhang Q, Zhan R, Luo S, Han Y, Yu B, Muss C, Pingault V, Marlin S, Delahaye A  et al.  Monoallelic loss-of-function variants in GSK3B lead to autism and developmental delay.  Mol Psychiatry  2024 Oct 29;. doi:10.1038/s41380-024-02806-z
  33. Elghetany MT, Pan JL, Sekar K, Major A, Mf Su J, Adesina A, Hui KM, Li XN, Teo WY  Re-programming by a six-factor-secretome in the patient tumor ecosystem during nutrient stress and drug response.  iScience  2024 Oct 18;27(10):110932. pii:110932
  34. Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC  et al.  Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.  Cancer Discov  2024 Oct 04;14(10):1823-1837. doi:10.1158/2159-8290.CD-23-1459
  35. van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F  et al.  The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?  Neuro Oncol  2024 Oct 03;26(10):1805-1822. doi:10.1093/neuonc/noae107
  36. Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P  et al.  Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.  Neuro Oncol  2024 Oct 03;26(10):1781-1804. doi:10.1093/neuonc/noae103
  37. Schwartz C, Ueberschaer MF, Rautalin I, Grauvogel J, Bissolo M, Masalha W, Steiert C, Schnell O, Beck J, Ebel F  et al.  Frailty indices predict mortality, complications and functional improvements in supratentorial meningioma patients over 80 years of age.  J Neurooncol  2024 Oct;170(1):89-100. doi:10.1007/s11060-024-04780-6
  38. Nguyen MP, Morshed RA, Youngblood MW, Perlow HK, Lucas CG, Patel AJ, Palmer JD, Horbinski CM, Magill ST, Chen WC  et al.  A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.  Neuro Oncol  2024 Sep 28;. pii:noae198
  39. Katz JL, Geng Y, Billingham LK, Sadagopan NS, DeLay SL, Subbiah J, Chia TY, McManus G, Wei C, Wang H  et al.  A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress.  Sci Rep  2024 Sep 20;14(1):21959. pii:21959
  40. Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Habashy K, Duffy J, Zhao J, Gould A, Chen L  et al.  MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacy.  bioRxiv  2024 Sep 18;. pii:2024.09.11.612571
  41. Schubert MC, Soyka SJ, Tamimi A, Maus E, Schroers J, Wißmann N, Reyhan E, Tetzlaff SK, Yang Y, Denninger R  et al.  Deep intravital brain tumor imaging enabled by tailored three-photon microscopy and analysis.  Nat Commun  2024 Sep 10;15(1):7383. pii:7383
  42. Zhang X, Duan S, Apostolou PE, Wu X, Watanabe J, Gallitto M, Barron T, Taylor KR, Woo PJ, Hua X  et al.  CHD2 Regulates Neuron-Glioma Interactions in Pediatric Glioma.  Cancer Discov  2024 Sep 04;14(9):1732-1754. doi:10.1158/2159-8290.CD-23-0012
  43. Panek WK, Toedebusch RG, Mclaughlin BE, Dickinson PJ, Van Dyke JE, Woolard KD, Berens ME, Lesniak MS, Sturges BK, Vernau KM  et al.  The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.  J Neurooncol  2024 Sep;169(3):647-658. doi:10.1007/s11060-024-04766-4
  44. Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y  et al.  Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases.  Am J Surg Pathol  2024 Sep 01;48(9):1146-1153. doi:10.1097/PAS.0000000000002264
  45. Sahm F, Aldape KD, Brastianos PK, Brat DJ, Dahiya S, von Deimling A, Giannini C, Gilbert MR, Louis DN, Raleigh DR  et al.  cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.  Neuro Oncol  2024 Aug 30;. pii:noae170
  46. Le Rhun E, Nayak L, Lim-Fat MJ, Rudà R, Pentsova E, Forsyth P, O'Brien BJ, Preusser M, Kumthekar P, Brandsma D  et al.  NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.  Neuro Oncol  2024 Aug 29;. pii:noae171
  47. Wang S, Castro BA, Katz JL, Arrieta V, Najem H, Vazquez-Cervantes GI, Wan H, Olson IE, Hou D, Dapash M  et al.  B cell-based therapy produces antibodies that inhibit glioblastoma growth.  J Clin Invest  2024 Aug 29;134(20). pii:e177384
  48. An S, McCortney K, Walshon J, Leonard K, Wray B, McCord M, DeCuypere M, Horbinski C  Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients.  Acta Neuropathol  2024 Aug 26;148(1):29. doi:10.1007/s00401-024-02795-x
  49. Tripathi S, Najem H, Dussold C, Pacheco S, Du R, Sooreshjani M, Hurley L, Chandler JP, Stupp R, Sonabend AM  et al.  Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma.  J Clin Invest  2024 Aug 13;134(19). pii:e177413
  50. Morshed RA, Nguyen MP, Youngblood MW, Perlow HK, Lucas CG, Patel AJ, Palmer JD, Chandler JP, Theodosopoulos PV, Magill ST  et al.  Gene Expression Changes Associated With Recurrence After Gross Total Resection of Newly Diagnosed World Health Organization Grade 1 Meningioma.  Neurosurgery  2024 Aug 05;. doi:10.1227/neu.0000000000003133
These are the publications from our team members that have been most recently indexed by PubMed. Visit PubMed to see more of our publications.

Follow MBTI on FacebookYouTubeLinkedInInstagram